8 results on '"Tennant, Sharon M."'
Search Results
2. Nontyphoidal salmonella disease: Current status of vaccine research and development.
- Author
-
Tennant, Sharon M., MacLennan, Calman A., Simon, Raphael, Martin, Laura B., and Khan, M. Imran
- Subjects
- *
SALMONELLA diseases , *BACTERIAL vaginitis , *SALMONELLA enterica serovar Typhi , *GASTROENTERITIS , *FOODBORNE diseases , *DISEASE incidence , *VACCINATION - Abstract
Among more than 2500 nontyphoidal Salmonella enterica (NTS) serovars, S. enterica serovar Typhimurium and S. enterica serovar Enteritidis account for approximately fifty percent of all human isolates of NTS reported globally. The global incidence of NTS gastroenteritis in 2010 was estimated to be 93 million cases, approximately 80 million of which were contracted via food-borne transmission. It is estimated that 155,000 deaths resulted from NTS in 2010. NTS also causes severe, extra-intestinal, invasive bacteremia, referred to as invasive nontyphoidal Salmonella (iNTS) disease. iNTS disease usually presents as a febrile illness, frequently without gastrointestinal symptoms, in both adults and children. Symptoms of iNTS are similar to malaria, often including fever (>90%) and splenomegaly (>40%). The underlying reasons for the high rates of iNTS disease in Africa are still being elucidated. Evidence from animal and human studies supports the feasibility of developing a safe and effective vaccine against iNTS. Both antibodies and complement can kill Salmonella species in vitro . Proof-of-principle studies in animal models have demonstrated efficacy for live attenuated and subunit vaccines that target the O-antigens, flagellin proteins, and other outer membrane proteins of serovars Typhimurium and Enteritidis. More recently, a novel delivery strategy for NTS vaccines has been developed: the Generalized Modules for Membrane Antigens (GMMA) technology which presents surface polysaccharides and outer membrane proteins in their native conformation. GMMA technology is self-adjuvanting, as it delivers multiple pathogen-associated molecular pattern molecules. GMMA may be particularly relevant for low- and middle-income countries as it has the potential for high immunologic potency at a low cost and involves a relatively simple production process without the need for complex conjugation. Several vaccines for the predominant NTS serovars Typhimurium and Enteritidis, are currently under development. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
3. Safety and tolerability of a live oral Salmonella typhimurium vaccine candidate in SIV-infected nonhuman primates.
- Author
-
Ault, Alida, Tennant, Sharon M., Gorres, J. Patrick, Eckhaus, Michael, Sandler, Netanya G., Roque, Annelys, Livio, Sofie, Bao, Saran, Foulds, Kathryn E., Kao, Shing-Fen, Roederer, Mario, Schmidlein, Patrick, Boyd, Mary Adetinuke, Pasetti, Marcela F., Douek, Daniel C., Estes, Jacob D., Nabel, Gary J., Levine, Myron M., and Rao, Srinivas S.
- Subjects
- *
SALMONELLA typhimurium , *VACCINATION , *BACTERIAL vaccines , *VACCINE safety , *ORAL medication , *LABORATORY monkeys , *DRUG tolerance - Abstract
Highlights: [ • ] An attenuated nontyphoidal Salmonella live oral vaccine is designed by deleting genes guaBA and clpP. [ • ] We test the safety of this vaccine in monkeys infected with simian immunodeficiency virus. [ • ] The vaccine was safe and well-tolerated, establishing basis for efficacy and protection studies. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
4. Mouse models to assess the efficacy of non-typhoidal Salmonella vaccines: Revisiting the role of host innate susceptibility and routes of challenge
- Author
-
Simon, Raphael, Tennant, Sharon M., Galen, James E., and Levine, Myron M.
- Subjects
- *
ENDOTOXINS , *SALMONELLA diseases , *DISEASE susceptibility , *GASTROENTERITIS , *DRUG efficacy , *DRUG development , *LABORATORY mice , *VACCINATION - Abstract
Abstract: Non-typhoidal Salmonella enterica (NTS) serovars Typhimurium and Enteritidis are important causes of bacterial gastroenteritis in the USA and worldwide. In sub-Saharan Africa these two serovars are emerging as agents associated with lethal invasive disease (e.g., bacteremia, meningitis). The development of NTS vaccines, based on mucosally administered live attenuated strains and parenteral non-living antigens, could diminish the NTS disease burden globally. Mouse models of S. Typhimurium and S. Enteritidis invasive disease can accelerate the development of NTS vaccines. Live attenuated NTS vaccines elicit both cellular and humoral immunity in mice and their efficacy is well established. In contrast, non-living vaccines that primarily elicit humoral immunity have demonstrated variable efficacy. An analysis of the reported studies with non-living vaccines against S. Typhimurium and S. Enteritidis reveals that efficacy is influenced by two important independent variables: (1) the innate susceptibility to NTS infection that differs dramatically between commonly used mouse strains and (2) the virulence of the NTS strain used for challenge. Protection by non-living vaccines has generally been seen only in host–pathogen interactions where a sub-lethal infection results, such as challenging resistant mice with either highly virulent or weakly virulent strains or susceptible mice with weakly virulent strains. The immunologic basis of this discrepancy and the implications for human NTS vaccine development are reviewed herein. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
5. Live attenuated vaccines for invasive Salmonella infections.
- Author
-
Tennant, Sharon M. and Levine, Myron M.
- Subjects
- *
BACTERIAL vaccines , *SALMONELLA diseases , *SALMONELLA enterica serovar Typhi , *VACCINE manufacturing , *EXCIPIENTS , *SALMONELLA enteritidis , *SALMONELLA enterica , *VACCINATION - Abstract
Salmonella enterica serovar Typhi produces significant morbidity and mortality worldwide despite the fact that there are licensed Salmonella Typhi vaccines available. This is primarily due to the fact that these vaccines are not used in the countries that most need them. There is growing recognition that an effective invasive Salmonella vaccine formulation must also prevent infection due to other Salmonella serovars. We anticipate that a multivalent vaccine that targets the following serovars will be needed to control invasive Salmonella infections worldwide: Salmonella Typhi, Salmonella Paratyphi A, Salmonella Paratyphi B (currently uncommon but may become dominant again), Salmonella Typhimurium, Salmonella Enteritidis and Salmonella Choleraesuis (as well as other Group C Salmonella ). Live attenuated vaccines are an attractive vaccine formulation for use in developing as well as developed countries. Here, we describe the methods of attenuation that have been used to date to create live attenuated Salmonella vaccines and provide an update on the progress that has been made on these vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
6. Understanding immunosenescence and its impact on vaccination of older adults.
- Author
-
Allen, Jessica C., Toapanta, Franklin R., Chen, Wilbur, and Tennant, Sharon M.
- Subjects
- *
IMMUNOSENESCENCE , *OLDER people , *VACCINATION , *VACCINE effectiveness , *COMMUNICABLE diseases , *HUMORAL immunity - Abstract
Older adults are more susceptible to viral and bacterial infection, and experience higher incidence and severity of infectious diseases. Although vaccination is the most logical solution in preventing infectious diseases, primary vaccine responses in individuals aged ≥65 years-old fail to generate complete protection. This is presumably attributed to immunosenescence, a term that describes functional differences associated with the immune system and natural age advancement. Both the innate and adaptive immune systems experience age-related impairments that contribute to insufficient protection following vaccination. This review addresses current knowledge of age-related changes that affect vaccine responsiveness; including the deficits in innate cell functions, dampened humoral and cell-mediated immune responses, current vaccination schedules for older adults, and concludes with potential strategies for improving vaccine efficacy specifically for this age group. Due to an age-related decline in immunity and poor vaccine responses, infectious diseases remain a burden among the aged population. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
7. Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial.
- Author
-
Tapia, Milagritos D, Sow, Samba O, Tamboura, Boubou, Tégueté, Ibrahima, Pasetti, Marcela F, Kodio, Mamoudou, Onwuchekwa, Uma, Tennant, Sharon M, Blackwelder, William C, Coulibaly, Flanon, Traoré, Awa, Keita, Adama Mamby, Haidara, Fadima Cheick, Diallo, Fatoumata, Doumbia, Moussa, Sanogo, Doh, DeMatt, Ellen, Schluterman, Nicholas H, Buchwald, Andrea, and Kotloff, Karen L
- Subjects
- *
INFLUENZA vaccines , *RANDOMIZED controlled trials , *CROSS-sectional method , *MENINGOCOCCAL infections , *PREGNANT women , *INFLUENZA prevention , *IMMUNOMODULATORS , *COMPARATIVE studies , *IMMUNIZATION , *INFLUENZA , *LONGITUDINAL method , *RESEARCH methodology , *MEDICAL cooperation , *MEDICAL protocols , *RESEARCH , *STATISTICAL sampling , *EVALUATION research , *MENINGOCOCCAL vaccines - Abstract
Background: Despite the heightened risk of serious influenza during infancy, vaccination is not recommended in infants younger than 6 months. We aimed to assess the safety, immunogenicity, and efficacy of maternal immunisation with trivalent inactivated influenza vaccine for protection of infants against a first episode of laboratory-confirmed influenza.Methods: We did this prospective, active-controlled, observer-blind, randomised phase 4 trial at six referral centres and community health centres in Bamako, Mali. Third-trimester pregnant women (≥28 weeks' gestation) were randomly assigned (1:1), via a computer-generated, centre-specific list with alternate block sizes of six or 12, to receive either trivalent inactivated influenza vaccine or quadrivalent meningococcal vaccine. Study personnel administering vaccines were not masked to treatment allocation, but allocation was concealed from clinicians, laboratory personnel, and participants. Infants were visited weekly until age 6 months to detect influenza-like illness; laboratory-confirmed influenza diagnosed with RT-PCR. We assessed two coprimary objectives: vaccine efficacy against laboratory-confirmed influenza in infants born to women immunised any time prepartum (intention-to-treat population), and vaccine efficacy in infants born to women immunised at least 14 days prepartum (per-protocol population). The primary outcome was the occurrence of a first case of laboratory-confirmed influenza by age 6 months. This trial is registered with ClinicalTrials.gov, number NCT01430689.Findings: We did this trial from Sept 12, 2011, to Jan 28, 2014. Between Sept 12, 2011, and April 18, 2013, we randomly assigned 4193 women to receive trivalent inactivated influenza vaccine (n=2108) or quadrivalent meningococcal vaccine (n=2085). There were 4105 livebirths; 1797 (87%) of 2064 infants in the trivalent inactivated influenza vaccine group and 1793 (88%) of 2041 infants in the quadrivalent meningococcal vaccine group were followed up until age 6 months. We recorded 5279 influenza-like illness episodes in 2789 (68%) infants, of which 131 (2%) episodes were laboratory-confirmed influenza. 129 (98%) cases of laboratory-confirmed influenza were first episodes (n=77 in the quadrivalent meningococcal vaccine group vs n=52 in the trivalent inactivated influenza vaccine group). In the intention-to-treat population, overall infant vaccine efficacy was 33·1% (95% CI 3·7-53·9); in the per-protocol population, vaccine efficacy was 37·3% (7·6-57·8). Vaccine efficacy remained robust during the first 4 months of follow-up (67·9% [95% CI 35·1-85·3] by intention to treat and 70·2% [35·7-87·6] by per protocol), before diminishing during the fifth month (57·3% [30·6-74·4] and 60·7 [33·8-77·5], respectively). Adverse event rates in women and infants were similar among groups. Pain at the injection site was more common in women given quadrivalent meningococcal vaccine than in those given trivalent inactivated influenza vaccine (n=253 vs n=132; p<0·0001), although 354 [92%] reactions were mild. Obstetrical and non-obstetrical serious adverse events were reported in 60 (3%) women in the quadrivalent meningococcal vaccine group and 61 (3%) women in the trivalent inactivated influenza vaccine group. Presumed neonatal infection was more common in infants in the trivalent inactivated influenza vaccine group than in those in the quadrivalent meningococcal vaccine group (n=60 vs n=37; p=0·02). No serious adverse events were related to vaccination.Interpretation: Vaccination of pregnant women with trivalent inactivated influenza vaccine in Mali-a poorly resourced country with high infant mortality-was technically and logistically feasible and protected infants from laboratory-confirmed influenza for 4 months. With adequate financing to procure the vaccine, implementation will parallel the access to antenatal care and immunisation coverage of pregnant women with tetanus toxoid.Funding: Bill & Melinda Gates Foundation. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
8. Status of paratyphoid fever vaccine research and development.
- Author
-
Martin, Laura B., Simon, Raphael, MacLennan, Calman A., Tennant, Sharon M., Sahastrabuddhe, Sushant, and Khan, M. Imran
- Subjects
- *
PARATYPHOID fever , *BACTERIAL vaccines , *DRUG development , *SALMONELLA enterica serovar Typhi , *TYPHOID fever , *ENDOTOXINS - Abstract
Salmonella enterica serovars Typhi and Paratyphi ( S . Paratyphi) A and B cause enteric fever in humans. Of the paratyphoid group, S . Paratyphi A is the most common serovar. In 2000, there were an estimated 5.4 million cases of S . Paratyphi A worldwide. More recently paratyphoid fever has accounted for an increasing fraction of all cases of enteric fever. Although vaccines for typhoid fever have been developed and in use for decades, vaccines for paratyphoid fever have not yet been licensed. Several S . Paratyphi A vaccines, however, are in development and based on either whole cell live-attenuated strains or repeating units of the lipopolysaccharide O-antigen (O:2) conjugated to different protein carriers. An O-specific polysaccharide (O:2) of S . Paratyphi A conjugated to tetanus toxoid (O:2-TT), for example, has been determined to be safe and immunogenic after one dose in Phase I and Phase II trials. Two other conjugated vaccine candidates linked to diphtheria toxin and a live-attenuated oral vaccine candidate are currently in preclinical development. As promising vaccine candidates are advanced along the development pipeline, an adequate supply of vaccines will need to be ensured to meet growing demand, particularly in the most affected countries. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.